Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

The authors would like to acknowledge Dana S. Neel, Manasi K. Mayekar, Beatrice Gini, Nilanjana Chatterjee, Ross A. Okimoto, Anatoly Urisman, Johannes R. Kratz, and Silvia Coma and Jonathan Pachter for their scientific input and experimental help. This research project was conducted with support from National Institutes of Health (NIH)/National Cancer Institute (NCI): U54CA224081 (T.G.B., C.J.K.) and U54 DRSN supplement (J.A.R.),The University of Texas MD Anderson Cancer Center's Cancer Center Support Grant (CCSG) CA-016672 - Lung Program and Shared Core Facilities (J.A.R.), Specialized Program of Research Excellence (SPORE) Grant CA-070907 (J.A.R.), PDX development and trial grant U54CA-224065 (J.A.R.), Lung Cancer Moon Shot Program (J.A.R.), U01 grants: U01CA217882 (T.G.B.), U01CA217851 (C.J.K.), R01 grants: R01CA231300 (T.G.B., B.H.), R01CA204302 (T.G.B.), R01CA211052 (T.G.B.), R01CA169338 (T.G.B.), R01-CA18731 (J.P.R.), R01GM131641 (B.H.); NIH/National Institute of Allergy and Infectious Diseases (NIAID): R01-AI104789 (J.P.R.); NIH/National Heart, Lung, and Blood Institute (NHLBI): R01 - HL120724 (J.P.R.); Verastem Oncology (T.G.B.); The University of Texas MD Anderson Cancer Center, sponsored research agreement from Genprex, Inc. (J.A.R.), UCSF PBBR TMC (Technologies, Methodologies, and Cores) grant, gift from the UCSF Pathology department (J.P.R.); Mark Foundation for Cancer Research, Endeavor Program grant A136299 (J.P.R.); The Ludwig Cancer Foundation (C.J.K.); Stand Up To Cancer Foundation (C.J.K.); The Damon Runyon Cancer Research foundation, P0528804 (C.M.B.); Doris Duke Charitable Foundation P2018110 (C.M.B.); V Foundation P0530519 (C.M.B.); The Van Auken Foundation and Addario Lung Cancer Foundation, Young Innovators Team Award (J.W.R.); Ministerio de Ciencia e Innovacion, Spain, PID2019-105303RB-I00/AEI/10.13039/501100011033 (P.S.); Comunidad de Madrid, Spain, B2017/BMD-3724 (P.S.); Fundacion Espanola Contra el Cancer (AECC), Spain, GCB14142311CRES (P.S.); FPI fellowship from Universidad Autonoma de Madrid, Spain (C.F.M.); Traveling Fellowship from The Company of Biologists (C.F.M.); the German Cancer Aid, Mildred Scheel postdoctoral fellowship (F.H.). B.H. is a Chan Zuckerberg Biohub Investigator. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 2038436. Any opinions, findings, conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation (L.C.). Postdoctoral Research Abroad Program (PRAP), Ministry of Science and Technology (MOST), Taiwan, 111-2917-I-564-019 (Y.C).